Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 3/20 | 0.34 |
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321498 | 0.69 | GSK3B (0.41) | GSK3AGSK3BGAAMAPTTDP1 | |
| SCHEMBL8335371 | 0.65 | KDM4E (0.31) | GSK3AGSK3BKDM4EGAAMAPT | |
| SCHEMBL7615549 | 0.60 | CA12 (0.32) | GSK3AGSK3B | |
| SCHEMBL8830916 | 0.59 | — | — | |
| SCHEMBL11001347 | 0.59 | CYP1A2 (0.31) | — | |
| SCHEMBL9717994 | 0.58 | MEN1 (0.41) | GSK3BNPSR1KDM4EMAPTTDP1 | |
| SCHEMBL10588430 | 0.58 | — | — | |
| SCHEMBL1565967 | 0.55 | CYP1A2 (0.33) | MAPT | |
| SCHEMBL3066766 | 0.54 | LMNA (0.32) | — | |
| SCHEMBL4899672 | 0.52 | LMNA (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-7176317-B2 | Colorant compounds | XEROX CORPORATION (US) | 2007-02-13 | — | — | US | disclosed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-6998493-B2 | Colorant compounds | XEROX CORPORATION (US) | 2006-02-14 | — | — | US | disclosed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | disclosed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-6860931-B2 | Phase change inks containing colorant compounds | XEROX CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-20050016417-A1 | PHASE CHANGE INKS CONTAINING COLORANT COMPOUNDS | XEROX CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-20050011410-A1 | Colorant compounds | XEROX CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20050011411-A1 | Colorant compounds | XEROX CORPORATION | 2005-01-20 | — | — | US | disclosed |
| EP-1493781-A1 | Rhodamine dye derivatives and their use for phase change inks | Xerox Corporation (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040261657-A1 | PHASE CHANGE INKS CONTAINING COLORANT COMPOUNDS | XEROX CORPORATION | 2004-12-30 | — | — | US | disclosed |
| US-6835238-B1 | Hot melts | XEROX CORPORATION | 2004-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050011411-A1 | Colorant compounds | CCNY, RB1, UQCRB | GSK3A 4044/4885GSK3B 3906/4885NPSR1 2425/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | GSK3A 3724/4885GSK3B 3368/4885NPSR1 2989/4885 |
| US-20050011410-A1 | Colorant compounds | CDYL, CDY1; CDY1B, RB1 | GSK3A 3732/4885GSK3B 4051/4885NPSR1 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.